A post-marketing surveillance of the real-world safety and effectiveness of avelumab in patients with curatively unresectable Merkel cell carcinoma in Japan

被引：2
|
作者：
Yamazaki, N. [1 ]
Kiyohara, Y. [2 ]
Sato, M. [3 ]
Endo, S. [4 ]
Song, B. [5 ]
Tanaka, Y. [6 ]
Kambe, A. [7 ]
Sato, Y. [6 ]
Uhara, H. [8 ]
机构：
[1] Natl Canc Ctr, Dermatol Oncol Dept, Tsukiji Campus,Chuo Ku, Tokyo, Japan
[2] Shizuoka Canc Ctr, Div Dermatol, Shizuoka, Japan
[3] Merck Biopharma Co Ltd, Biostat, Meguro Ku, Tokyo, Japan
[4] Merck Biopharma Co Ltd, Dev Safety Japan, Meguro Ku, Tokyo, Japan
[5] Merck Biopharma Co Ltd, Clin Data Sci, Meguro Ku, Tokyo, Japan
[6] Merck Biopharma Co Ltd, Affairs Sect, Meguro Ku, Tokyo, Japan
[7] Merck Biopharma Co Ltd, PMS, Meguro Ku, Tokyo, Japan
[8] Sapporo Med Univ, Dept Dermatol, Sch Med, Sapporo, Hokkaido, Japan
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.438
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
407P
引用
收藏
页码：S1601 / S1602
页数：2
相关论文
共 50 条
  • [1] Safety and effectiveness of avelumab in patients with curatively unresectable merkel cell carcinoma (MCC) in a real-world setting: A post-marketing surveillance in Japan.
    Uhara, Hisashi
    Kiyohara, Yoshio
    Sato, Masashi
    Endo, Shehla
    Song, Bingbing
    Sato, Yoshinori
    Tanaka, Yutaro
    Kambe, Anzu
    Yamazaki, Naoya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Safety and effectiveness of avelumab in patients with Merkel cell carcinoma in general clinical practice in Japan: Post-marketing surveillance
    Uhara, Hisashi
    Kiyohara, Yoshio
    Isei, Taiki
    Nagase, Kotaro
    Kambe, Anzu
    Sato, Masashi
    Tanaka, Yutaro
    Yamazaki, Naoya
    [J]. JOURNAL OF DERMATOLOGY, 2024, 51 (04): : 475 - 483
  • [3] Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance
    Hirotsugu Uemura
    Yoshihiko Tomita
    Norio Nonomura
    Kenji Yoshizaki
    Takafumi Nakao
    Nobuo Shinohara
    [J]. International Journal of Clinical Oncology, 2022, 27 : 1061 - 1067
  • [4] Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance
    Uemura, Hirotsugu
    Tomita, Yoshihiko
    Nonomura, Norio
    Yoshizaki, Kenji
    Nakao, Takafumi
    Shinohara, Nobuo
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (06) : 1061 - 1067
  • [5] Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan
    Furuse, Junji
    Izumi, Namiki
    Motomura, Kenta
    Inaba, Yoshitaka
    Katamura, Yoshio
    Kondo, Yasuteru
    Yabushita, Kazuhisa
    Motoyoshi, Katsuaki
    Kudo, Masatoshi
    [J]. DRUGS-REAL WORLD OUTCOMES, 2023, 10 (02) : 195 - 205
  • [6] Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan
    Junji Furuse
    Namiki Izumi
    Kenta Motomura
    Yoshitaka Inaba
    Yoshio Katamura
    Yasuteru Kondo
    Kazuhisa Yabushita
    Katsuaki Motoyoshi
    Masatoshi Kudo
    [J]. Drugs - Real World Outcomes, 2023, 10 : 195 - 205
  • [7] Real-world safety and effectiveness of lenvatinib in unresectable hepatocellular carcinoma in Korea: post-marketing study
    Kang, Wonseok
    Kim, Yoon Jun
    Kim, Seung Up
    Seo, Yeon Seok
    Kim, Jin-Wook
    Kim, Ji Hoon
    Park, Soo Young
    Baek, Yang-Hyun
    Kim, Kang Mo
    Lee, Hae Lim
    Yoon, Ki Tae
    Kim, Hyeyeong
    Cheong, Jae Youn
    Hwang, Jae Seok
    Kim, Ju Hyun
    Kim, Kwang Min
    Sung, Pil Soo
    Kim, Jieun
    Kim, Do Young
    [J]. FUTURE ONCOLOGY, 2024,
  • [8] The real-world use of istradefylline for Parkinsons disease: Post-marketing surveillance of safety and effectiveness in Japan
    Takahashi, Makio
    Itou, Satoru
    Horiguchi, Shuji
    Tsuji, Yukie
    [J]. NEUROLOGY, 2022, 98 (18)
  • [9] Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance
    Maruyama, Dai
    Omi, Ai
    Nomura, Fumi
    Touma, Tokiko
    Noguchi, Yukiko
    Takebe, Kyoko
    Izutsu, Koji
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 119 (02) : 146 - 155
  • [10] Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance
    Dai Maruyama
    Ai Omi
    Fumi Nomura
    Tokiko Touma
    Yukiko Noguchi
    Kyoko Takebe
    Koji Izutsu
    [J]. International Journal of Hematology, 2024, 119 : 146 - 155
12345